Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSPCAMACHO, M.CARVALHO, M.MUNHOZ, R.ETCHEBEHERE, M.ETCHEBEHERE, E.2023-12-042023-12-042022Camacho, M.; Carvalho, M.; Munhoz, R.; Etchebehere, M.; Etchebehere, E.. FDG PET/CT in bone sarcomas. In: . Nuclear Medicine and Molecular Imaging: Volume 1-4, v.3: ELSEVIER, 2022. p.445-465.978-012822980-4; 978-012822960-6https://observatorio.fm.usp.br/handle/OPI/57247Bone sarcomas are a rare and diverse group of malignant neoplasms composed by entities with distinct presentations, clinical courses and therapeutic approaches. Although bone sarcomas may affect all age groups, these tumors exhibit a bimodal distribution, with higher incidences in children and in the elderly. Imaging exams are a crucial step for an adequate evaluation of bone sarcomas and mandatory for treatment planning, and provide invaluable information regarding disease extent, prognostic information, treatment response, and disease relapse.Whole-body FDG PET/CT imaging may be a part of the diagnostic work-up of bone sarcomas. FDG PET/CT combines, in a single study, morphologic and metabolic information that may alter treatment strategies, help guide or avoid unnecessary biopsies, stage patients, determine the degree of tumor necrosis following neoadjuvant chemotherapy, detect local recurrence, and provide important prognostic information. This article will discuss the current and potential roles of FDG PET/CT in osteosarcoma, Ewing's sarcoma, chondrosarcoma, giant cell bone tumor, and chordoma. © 2022 Elsevier Inc. All rights reserved.engrestrictedAccess18F-FDGBone sarcomaChondrosarcomaChordomaEwing's sarcomaGiant cell tumorOsteosarcomaPET/CTbookPartCopyright ELSEVIER10.1016/B978-0-12-822960-6.00062-4